Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd

# TUSQ-QD ## Overview TUSQ-QD is a fixed-dose combination product containing **tumaril** (a novel serotonin 5-HT1A receptor partial agonist) and **quetiapine fumarate** (an atypical antipsychotic). Tumaril is thought to modulate mood and anxiety, while quetiapine exerts its effects through antagonism of dopamine D2 and serotonin 5-HT2A receptors. ## Primary Indications * Major Depressive Disorder (MDD) in adults. ## Adult Dosing * **Recommended dose:** One tablet orally once daily. * **Maximum dose:** Not explicitly defined in available information, but individual component maximums should be considered (e.g., quetiapine typically up to 300 mg/day for MDD). ## Pediatric Dosing * Safety and efficacy in pediatric patients have not been established. ## Dose Adjustments * **Hepatic Impairment:** No specific guidance for the combination product. Tumaril and quetiapine may require dose reduction; caution and careful titration are advised. * **Renal Impairment:** No specific guidance for the combination product. Tumaril and quetiapine generally do not require dose adjustment for mild to moderate renal impairment. Severe impairment data is limited. ## Contraindications * Hypersensitivity to tumaril, quetiapine, or any component of the formulation. * Concomitant use with strong CYP3A4 inhibitors (for quetiapine component). ## Adverse Effects * Commonly reported adverse effects include: somnolence, dry mouth, dizziness, constipation, nausea, headache, asthenia, and orthostatic hypotension. * Serious adverse effects may include: suicidal thoughts and behaviors (especially in young adults), extrapyramidal symptoms (EPS), neuroleptic malignant syndrome (NMS), metabolic changes (hyperglycemia, dyslipidemia, weight gain), cataracts, and QT prolongation. ## Key Drug Interactions * **CYP3A4 Inhibitors/Inducers:** Tumaril is metabolized by CYP3A4. Quetiapine is also a substrate for CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) can increase tumaril and quetiapine levels. Strong CYP3A4 inducers (e.g., rifampin) can decrease levels. * **CNS Depressants:** Additive CNS depressant effects with alcohol, benzodiazepines, and other sedating agents. * **Antihypertensives:** Quetiapine may enhance the effect of certain antihypertensive agents. * **QTc Prolonging Agents:** Caution with other drugs known to prolong the QTc interval. ## Monitoring * Monitor for suicidal ideation and behavior, particularly at the initiation of therapy and during dose changes. * Monitor for signs and symptoms of EPS and NMS. * Regularly monitor weight, fasting glucose, and lipid profiles. * Assess for orthostatic hypotension and dizziness. * Ophthalmic examinations for cataracts should be considered periodically. ## Clinical Pearls * TUSQ-QD should be taken once daily, preferably at bedtime due to potential somnolence. * Gradual titration is recommended when initiating therapy or increasing the dose. * Patients should be advised against driving or operating heavy machinery until they know how TUSQ-QD affects them. * Discontinuation should be gradual to avoid withdrawal symptoms. *** *This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions regarding a medical condition or treatment. Verify the most current prescribing information with the manufacturer's official product documentation.*